Abstract 918
Background
Aim of this study was to identify antioxidant and anticancer compounds present in the C. viminalis leaves extracts and its anticancer activity against liver cancer cell lines by inhibiting STAT3 protein.
Methods
The free radical scavenging potential of various extract of C. viminalis leaves were determined by the DPPH, superoxide anion radical scavenging, hydrogen peroxide scavenging, nitric oxide scavenging and reducing power assay. The anticancer activity of C. viminalis leaves extracts have been evaluated against human embryonic kidney (HEK-293) cell line, human liver cancer (HepG-2) and breast cancer (MCF-7) cell lines. The chemical composition of C. viminalis is analyzed by gas chromatography/mass spectrometry (GC-MS).
Results
The results were revealed that ELE and MLE extracts of C. viminalis are better sources of antioxidants. ELE and MLE extracts reduced HepG-2 cell growth and ROS generation. Interestingly, our result indicates that reduction in potential of cell migration enhances anti-metastasis activity of ELE and MLE and induction of apoptosis and cell cycle arrest in G0/G1 and S phase, suggesting the ELE and MLE extracts induced apoptosis and reduce the cell proliferation. ELE and MLE reduced the STAT3 mRNA expression and increased the p53 mRNA expression, as confirmed by RTPCR and also reduced the STAT3 protein expression and increased the p53 protein expression, as confirmed by western blot. The anticancer activity of ELE and MLE extracts against liver cancer cell lines by inhibiting of STAT3 protein are possibly due to presence of active anticancer compounds identified by GC/MS. Molecular docking results revealed that the hydrophobic and hydrogen bond interactions are the main force for binding of compounds of extracts ELE and MLE with the STAT3.
Conclusions
The ELE and MLE extracts reduces the cell proliferation against liver cancer cell lines by inhibiting of STAT3 protein and can be successfully exploited in the herbal formulation of cancer chemoprevention and chemotherapy.
Clinical trial identification
Legal entity responsible for the study
Jamia Millia Islamia
Funding
None
Disclosure
All authors have declared no conflicts of interest.